Jiménez JJR, Castellanos RK

Idioma: Español
Referencias bibliográficas: 26
Paginas: 265-270
Archivo PDF: 80.85 Kb.

RESUMEN

El surfactante pulmonar exógeno es actualmente pieza fundamental en el manejo del síndrome de dificultad respiratoria del recién nacido, por tal motivo es de interés el conocimiento de los tipos disponibles en el mercado, así como algunos de sus antecedentes y propiedades. El propósito de este artículo es informar dosis, componentes e indicaciones de los principales tipos de surfactante pulmonar.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Villanueva GD, Fernández MP, Hernáiz AM. Desarrollo del sistema pulmonar y surfactante. En: Insuficiencia respiratoria neonatal, PAC Neonatología 1 libro 3 Intersistemas; 2003: 143-4.

2. Jasso GL, Vargas OA, Villegas SR. Síndrome de dificultad respiratoria. En: Arellano PM, editores. Cuidados intensivos en pediatría. 3a edición. México: Interamericana McGraw-Hill; 1994: 206-19.

3. Salinas RV, Zapata PJ. Surfactante pulmonar. En: Rodríguez WM, Udaeta ME editores. Neonatología clínica. México: McGraw-Hill; 2004: 265-74.

4. Sinha S, Moya F, Donn S. Surfactant for respiratory distress syndrome: are there important clinical differences among preparations? Curr Opin Pediatr 2007; 19: 150-4.

5. Craig LM, Sean BA. An update on the use of surfactant in neonates. Current Pediatrics 2004; 14: 284-9.

6. Lyra PP, Diniz EM. The importance of surfactant on the development of neonatal pulmonary diseases. Clinics (São Paulo). 2007; 62(2): 181-90.

7. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1(8159): 55-9.

8. Engle WA; American Academy of Pediatrics Committee on fetus and newborn. Surfactant replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008; 121(2): 419-32.

9. Jobe AH. Pharmacology review: Why surfactant works for respiratory distress syndrome. Neo Reviews 2006; 7: e95-e106.

10. Kattwinkel J. Surfactant. Evolving issues. Clin Perinatol 1998; 25: 17-32.

11. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infant. Cochrane Database Syst Rev 2000; (2): CD000511.

12. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000; (2): CD 001079.

13. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2001; (2): CD 000510.

14. Gortner L, Wauer RR, Hammer H, Stock GJ, Heitmann F, Reiter HL et al. Early versus late surfactant treatment in preterm infants of 27 to 32 weeks gestational age: A multicenter controlled clinical trial. Pediatrics 1998; 102(5): 1153-60.

15. Tooley WH, Clements JA, Muramatsu K, Brown CL, Schlueter MA. Lung function in prematurely delivered rabbits treated with a synthetic surfactant. Am Rev Respir Dis 1987; 136(3): 651-6.

16. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group. Pediatrics 1988; 82(5): 683-91.

17. Bhutani VK, Abbasi S, Long WA, Gerdes JS. Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant. J Pediatr 1992; 120(2 Pt 2): S18-24.

18. Billman D, Nicks J, Schwmacher R. Exosurf rescue surfactant improves high ventilation-perfusion mismatch in respiratory distress syndrome. Pediatr Pulmonol 1994; 18(5): 279-83.

19. Hamdan AH, Shaw NJ. Changes in pulmonary artery pressure during the acute phase of respiratory distress syndrome treated with three different types of surfactant. Pediatr Pulmonol 1998; 25(3): 191-5.

20. Kääpä P, Seppänen M, Kero P, Saraste M. Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. J Pediatr 1993; 123(1): 115-9.

21. Skinner J. The effects of surfactant on haemodynamics in hyaline membrane disease. Arch Dis Child Fetal Neonatal Ed 1997; 76(2): F67-9.

22. Bihar Pedicon 2006. Bihar: Conference abstract on pediatric oncall. Accesible en: http://www.pediatriconcall.com

23. Sinha SK, Lacaze-Masmonteil T, Valls I, Soler A, Wiswell TE, Gadzinowski J, Hajdu J et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115(4): 1030-8.

24. Blanco HO. Propiedades antiinflamatorias del surfactante pulmonar y su aplicación en la clínica. Biotecnología Aplicada 2004; 21: 70-76.

25. Young TE, Mangum B. Surfactantes: en Neo Fax, ver 9.0.8/2006.11.9 Skyscape palm software.

26. Moya F, Sinha S, Gadzinowski J, D’Agostino R, Segal R, Guardia C et al. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics 2007; 119(6): e1361-70.